Joks G

Medical & Scientific Affairs, Janssen-Cilag Pty Ltd, Sydney, Australia.

2 papers · ORCID

ArticleKetamine

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): commentary, Joks et al.

Joks G, Su S, King J

Europe PMC2024
ArticleKetamine

Establishing an esketamine clinic in Australia: Practical recommendations and clinical guidance from an expert panel.

Thornton NLR, Black W, Bognar A +10

Europe PMC2023